Cancer vaccine pp65 - Immunomic Therapeutics/Duke University

Drug Profile

Cancer vaccine pp65 - Immunomic Therapeutics/Duke University

Alternative Names: CMV pp65-LAMP mRNA-loaded dendritic cells; CMV RNA-Pulsed dendritic cells; Cytomegalovirus pp65-LAMP mRNA-loaded dendritic cells; flLAMP-pp65; LAMP + pp65 DC; pp65-flLAMP DC; pp65-shLAMP DC; shLAMP-pp65

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duke University Medical Center; Immunomic Therapeutics
  • Developer Duke University Medical Center; National Cancer Institute (USA); University of Florida
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants; Interleukin 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma

Most Recent Events

  • 22 Nov 2017 Pharmacodynamics data from a preclinical trial in Glioblastoma released by Immunomic Therapeutics
  • 15 May 2017 Duke University has patent protection for cytomegalovirus immunotherapy plaform
  • 04 Oct 2016 Immunomic Therapeutics in-licenses NTC’s RNA-OUT™ and HyperGro™ technology from Nature Technology Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top